Italia markets closed

Teva Pharmaceutical Industries Limited (TEVJF)

OTC Markets OTCPK - OTC Markets OTCPK Prezzo differito. Valuta in USD.
Aggiungi a watchlist
17,240,00 (0,00%)
Alla chiusura: 09:50AM EDT

Teva Pharmaceutical Industries Limited

124 Dvora HaNevi’a Street
Tel Aviv 6944020
972 3 914 8213

SettoreDrug Manufacturers - Specialty & Generic
Impiegati a tempo pieno35.001

Figure dirigenziali chiave

NomeTitoloRetribuzioneEsercitateAnno di nascita
Mr. Richard D. FrancisPresident, CEO & Director6,71MN/D1968
Mr. Eliyahu Sharon KalifExecutive VP & CFO1,94MN/D1974
Mr. Mark SabagExecutive Vice President of International Markets Commercial1,73MN/D1971
Mr. Richard Gordon DaniellExecutive Vice President of European Commercial1,66MN/D1967
Mr. Matthew ShieldsExecutive Vice President of Global OperationsN/DN/D1974
Mr. Amir WeissSenior VP & Chief Accounting OfficerN/DN/D1977
Ran MeirHead of Investor RelationsN/DN/DN/D
Kathleen VeitSenior Vice President, Global Compliance & Ethics OfficerN/DN/DN/D
Mr. David R. Mcavoy J.D.Executive VP & Chief Legal OfficerN/DN/D1963
Ms. Vikki ConwayActing Head of Global Human ResourcesN/DN/D1972
Gli importi risalgono al giorno 31 dicembre 2023 e i valori di compensazione riguardano l'anno fiscale che si chiude a tale data. La retribuzione include salari, bonus ecc. "Esercitate" è il valore delle opzioni esercitate durante l'anno fiscale. Valuta in USD.


Teva Pharmaceutical Industries Limited develops, manufactures, markets, and distributes generic medicines, specialty medicines, and biopharmaceutical products in North America, Europe, Israel, and internationally. It offers generic medicines in various dosage forms, such as tablets, capsules, injectables, inhalants, liquids, transdermal patches, ointments, and creams; sterile products, hormones, high-potency drugs, and cytotoxic substances in parenteral and solid dosage forms; and generic products with medical devices and combination products. The company focuses on the central nervous system (CNS), respiratory, and oncology areas. It provides active pharmaceutical ingredients, as well as contract manufacturing services; and operates an out-licensing platform that offers a portfolio of products to other pharmaceutical companies. The company also offers BENDEKA and TREANDA injections for the treatment of chronic lymphocytic leukemia and indolent b-cell non-hodgkin's lymphoma; GRANIX; TRISENOX; LONQUEX; and TEVAGRASTIM/RATIOGRASTIM. In addition, it provides COPAXONE for the treatment of relapsing forms of multiple sclerosis; AJOVY for the preventive treatment of migraine in adults; AUSTEDO for the treatment of neurodegenerative and movement disorders associated with Huntington's disease and tardive dyskinesia; UZEDY for the treatment of schizophrenia; ProAir RespiClick inhalation powder; QVAR for treatment for asthma; BRALTUS, a long-acting muscarinic antagonist; CINQAIR/CINQAERO injection; DuoResp Spiromax, an inhaled corticosteroid and long-acting beta-agonist bronchodilator; and AirDuo RespiClick fluticasone propionate and salmeterol inhalation powder. The company offers its OTC products under SUDOCREM, NasenDuo, DICLOX FORTE, OLFEN Max, and FLEGAMINA brand names. It has collaboration agreements with MedinCell; Sanofi; Alvotech; and Biolojic Design Ltd., as well as license agreement with MODAG GmbH. The company was founded in 1901 and is based in Tel Aviv, Israel.

Governance aziendale

L'ISS Governance QualityScore di Teva Pharmaceutical Industries Limited al 1 giugno 2024 è 5. I criteri di valutazione fondamentali sono revisione: 9; Consiglio di Amministrazione: 3; diritti degli azionisti: 5; retribuzione: 6.

Punteggi di corporate governance forniti da Institutional Shareholder Services (ISS). I punteggi indicano il rango decile relativo all’indice o alla regione. Un punteggio di decile pari a 1 indica un governance risk più basso, mentre un punteggio di 10 indica un governance risk più alto.